Please wait a minute...
浙江大学学报（医学版）
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (3): 297-301    DOI: 10.3785/j.issn.1008-9292.2020.04.02
    
Efficacy and safety of letrozole in treatment of male children with disorders of sex development
YU Bingqing(),NIE Min,WU Xueyan*(),MAO Jiangfeng,WANG Xi,MA Wanlu,JI Wen,HUANG Qibin,ZHANG Rui
Department of Endocrinology, National Health Commission Key laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
Download: HTML( 8 )   PDF(1014KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To investigate the efficacy and safety of aromatase inhibitor letrozole in treatment of male children with disorders of sex development (DSD). Methods: Clinical data of 12 male DSD children with a mean age of 14.6±2.5 years admitted to Peking Union Medical College Hospital from January 2014 to January 2016 were retrospectively analyzed. The patients were treated with letrozole (1.25-2.5 mg, once a day) for 3 months or longer, and followed up for 0.5-2.5 years. Clinical manifestation and laboratory test findings were documented, and the efficacy and safety were evaluated. Results: After half-year treatment, the blood luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone levels of patients increased (all P < 0.05), and estrogen levels decreased from baseline (P < 0.05). After 1 year of treatment, the blood testosterone level was significantly higher (P < 0.05); the LH and FSH levels tended to increase and the estrogen level tended to decrease, but there was no significant statistical difference (P>0.05). Semen was routinely detected in 8 patients, and sperms were detected in semen of 3 patients with hypospadias. There were no significant changes in biochemical results after treatment, and no significant adverse event was observed during the treatment. Conclusion: Letrozole can effectively increase testosterone levels in patients with disorders of sex development and promote spermatogenesis, it has no significant adverse effects in short-term administration.

Key words： Disorders of sex development/drug therapy      Aromatase inhibitors/therapeutic use      Letrozole      Testosterone      Child      Disorders of sex development/drug therapy      Aromatase inhibitors/therapeutic use      Letrozole      Testosterone      Child     
Received: 15 December 2019      Published: 29 May 2020
CLC:  R588  
  R725.8  
  R588  
  R725.8  
Corresponding Authors: WU Xueyan     E-mail: 113ybq@sina.com;wsheyan@vip.sina.com
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
YU Bingqing
NIE Min
WU Xueyan
MAO Jiangfeng
WANG Xi
MA Wanlu
JI Wen
HUANG Qibin
ZHANG Rui
Cite this article:

YU Bingqing,NIE Min,WU Xueyan,MAO Jiangfeng,WANG Xi,MA Wanlu,JI Wen,HUANG Qibin,ZHANG Rui. Efficacy and safety of letrozole in treatment of male children with disorders of sex development. J Zhejiang Univ (Med Sci), 2020, 49(3): 297-301.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.04.02     OR     http://www.zjujournals.com/med/Y2020/V49/I3/297


来曲唑有效提高性发育异常男性患儿的睾酮水平

目的: 评价第三代非甾体类芳香化酶抑制剂来曲唑治疗男性性发育异常（DSD）患儿的疗效和安全性。方法: 收集2014年1月至2016年1月就诊于北京协和医院内分泌科门诊的男性DSD患儿12例，来曲唑治疗（1.25~2.5 mg，1次/d）不少于3个月，随访半年至2.5年。采集其临床资料及实验室检查结果，比较治疗前后激素水平及生化指标的差异，并观察治疗中的不良反应。结果: 本组患儿来曲唑治疗的平均年龄为（14.6±2.5）岁。来曲唑治疗半年后患者血促性腺激素黄体生成素（LH）、卵泡刺激素（FSH）及睾酮水平较基线升高（均P < 0.05），雌二醇水平较基线下降（P < 0.05）；治疗1年后患者睾酮水平较基线高（P < 0.05），LH及FSH水平较基线高，雌二醇水平较基线下降，但差异无统计学意义（均P>0.05）。8例患儿进行精液常规检测，其中3例尿道下裂患儿精液中可检测到精子。所有患儿治疗前后生化检查无明显变化，用药后无明显不良反应。结论: 来曲唑可有效提高DSD患儿的睾酮水平，促进精子生成，且短期应用未见明显不良反应。


关键词： 性发育障碍/药物疗法,  芳香酶抑制剂/治疗应用,  来曲唑,  睾酮,  儿童,  性发育障碍/药物疗法,  芳香酶抑制剂/治疗应用,  来曲唑,  睾酮,  儿童 
检测时间 n 黄体生成素(U/L) 卵泡刺激素(U/L) 睾酮(nmol/L) 雌二醇(pmol/L)
正常值范围：黄体生成素为1.24~8.62 U/L, 卵泡刺激素为1.27~19.26 U/L, 睾酮为6.1~27.1 nmol/L, 雌二醇为0~168.8 pmol/L.与治疗前比较, *P＜0.05.
治疗前 12 5.2(3.7, 16.5) 14.1(5.3, 24.7) 5.2(3.8, 10.0) 120.7±51.0
治疗后半年 12 16.2(10.1, 23.2)* 37.7(17.9, 49.6)* 20.1(5.9, 28.1)* 64.9±55.1*
治疗后一年 12 13.0(4.0, 21.3) 39.8(6.2, 40.5) 19.7(7.9, 27.4)* 71.2±50.6
Tab 1 Hormone levels before and after letrozole treatment in patients with disorders of sex development [M(Q1, Q3)或$\bar x \pm s$]
检测时间 n ALT(U/L) AST(U/L) GGT(U/L) 总胆红素(μmol/L) 直接胆红素(μmol/L) 肌酐(μmol/L) 尿素(μmol/L)
“—”：无相关数据.ALT:丙氨酸转氨酶；AST:天冬氨酸转氨酶；GGT:谷氨酰转移酶.
治疗前 12 24±15 23±6 30±16 12±3 4.5±1.5 61.4±15.9 4.3±0.9
治疗后 12 25±6 22±4 35±18 12±6 4.3±2.4 73.0±11.7 4.5±1.2
t值 — -0.155 0.177 -0.500 -0.038 0.253 -1.611 -0.440
P值 — ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＞0.05 ＞0.05
Tab 2 Comparison of biochemical parameters before and after letrozole treatment in patients with disorders of sex development (${\bar x}$±s)
[1]   RAMAN J D , SCHLEGEL P N . Aromatase inhibitors for male infertility[J]. J Urol, 2002, 167 (2 Pt 1): 624- 629
doi: 10.1097/00005392-200202000-00038
[2]   DEL GIUDICE F , BUSETTO G M , DE BERARDINIS E et al. A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility[J]. Asian J Androl, 2019,
doi: 10.4103/aja.aja_101_19
[3]   TAN R B , GUAY A T , HELLSTROM W J . Clinical use of aromatase inhibitors in adult males[J]. Sex Med Rev, 2014, 2 (2): 79- 90
doi: 10.1002/smrj.23
[4]   刘兆祥, 茅江峰, 伍学焱 et al. 芳香化酶抑制剂(来曲唑)可有效治疗男性部分性特发性低促性腺激素性性腺功能减退症[J]. 中华内分泌代谢杂志, 2016, 32 (2): 125- 127
LIU Zhaoxiang , MAO Jiangfeng , WU Xueyan et al. Aromatase inhibitor (letrozole) in effective in activating the function of hypothalamus-pituitary-gonad axis in male patients with partial idiopathic hypogonadotropic hypogonadism[J]. Chinese Journal of Endocrinology and Metabolism, 2016, 32 (2): 125- 127
doi: 10.3760/cma.j.issn.1000-6699.2016.02.009
[5]   LOVES S , DE JONG J , VAN SORGE A et al. Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia[J]. Eur J Endocrinol, 2013, 169 (5): 705- 714
doi: 10.1530/EJE-13-0190
[6]   MITWALLY M F , CASPER R F . Aromatase inhibitors for the treatment of infertility[J]. Expert Opin Investig Drugs, 2003, 12 (3): 353- 371
doi: 10.1517/13543784.12.3.353
[7]   WISNIEWSKI A B , BATISTA R L , COSTA E et al. Management of 46, xy differences/disorders of sex development (dsd) throughout life[J]. Endocr Rev, 2019, 40 (6): 1547- 1572
doi: 10.1210/er.2019-00049
[8]   MEHTA A , CLEARMAN T , PADUCH D A . Safety and efficacy of testosterone replacement therapy in adolescents with Klinefelter syndrome[J]. J Urol, 2014, 191 (5 Suppl): 1527- 1531
doi: 10.1016/j.juro.2013.09.015
[9]   MEHTA A , BOLYAKOV A , ROOSMA J et al. Successful testicular sperm retrieval in adolescents with Klinefelter syndrome treated with at least 1 year of topical testosterone and aromatase inhibitor[J]. Fertil Steril, 2013, 100 (4): 970- 974
doi: 10.1016/j.fertnstert.2013.06.010
[10]   SCHIFF J D , PALERMO G D , VEECK L L et al. Success of testicular sperm extraction[corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome[J]. J Clin Endocrinol Metab, 2005, 90 (11): 6263- 6267
doi: 10.1210/jc.2004-2322
[11]   MOON J E , KO C W , YANG J D et al. Combined surgical and medical treatment in an adolescent with severe gynecomastia due to excessive estradiol secretion:a case report[J]. BMC Pediatr, 2019, 19 (1): 515
doi: 10.1186/s12887-019-1887-7
[12]   MA N S , GEFFNER M E . Gynecomastia in prepubertal and pubertal men[J]. Curr Opin Pediatr, 2008, 20 (4): 465- 470
doi: 10.1097/MOP.0b013e328305e415
[13]   SALTZSTEIN D , SIEBER P , MORRIS T et al. Prevention and management of bicalutamide-induced gynecomastia and breast pain:randomized endocrinologic and clinical studies with tamoxifen and anastrozole[J]. Prostate Cancer Prostatic Dis, 2005, 8 (1): 75- 83
doi: 10.1038/sj.pcan.4500782
[14]   PARADA-BUSTAMANTE A , RíOS R , EBENSPERGER M et al. 46, XX/SRY-negative true hermaphrodite[J]. Fertil Steril, 2010, 94 (6): 2330
doi: 10.1016/j.fertnstert.2010.03.066
[1] LI Yanhong,DU Minlian,MA Huamei,CHEN Qiuli,CHEN Hongshan,ZHANG Jun. Efficacy of letrozole in treatment of male adolescents with idiopathic short stature[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 308-314.
[2] WANG Chunlin,LIANG Li. Reconsideration of the third-generation non-steroidal aromatase inhibitors in pediatrics[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 275-282.
[3] XU De,LU Wenli,WANG Xueqing,WANG Junqi,XIE Yiwen,DONG Zhiya,WANG Wei. Efficacy and safety of letrozole in treatment of McCune-Albright syndrome girls with peripheral precocious puberty[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 291-296.
[4] WANG Qian,ZHANG Shule,MA Xue,LI Guimei,WANG Zengmin,WANG Fengxue. Efficacy of letrozole in treatment of children with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency[J]. J Zhejiang Univ (Med Sci), 2020, 49(3): 302-307.
[5] CHEN Zhimin,FU Junfen,SHU Qiang,WANG Wei,CHEN Yinghu,HUA Chunzhen,LI Fubang,LIN Ru,TANG Lanfang,WANG Tianlin,WANG Yingshuo,XU Weize,YANG Zihao,YE Sheng,YUAN Tianming,ZHANG Chenmei,ZHANG Yuanyuan. Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition)[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 139-146.
[6] LIN Jing,CHEN Zhimin. Research progress on early identification of severe adenovirus pneumonia in children[J]. J Zhejiang Univ (Med Sci), 2019, 48(5): 567-572.
[7] NIU Yubai,ZHANG Lingyan,HAO Zesheng,JI Yuzhu. Relationship between temperament, parenting style and resilience of children aged 3-5 years[J]. J Zhejiang Univ (Med Sci), 2019, 48(1): 75-82.
[8] XU Weize,YE Jingjing,LI Jianhua,ZHANG Zewei,YU Jiangen,SHI Zhuo,YU Jin,SHU Qiang. Efficacy of percutaneous atrial septal defect closure guided by transesophageal echocardiography in children[J]. J Zhejiang Univ (Med Sci), 2018, 47(3): 244-249.
[9] SONG Chunze,JIANG Guoping,YE Jingjing,HE Jin,YU Jin. Echocardiography in diagnosis of pediatric pulmonary artery sling[J]. J Zhejiang Univ (Med Sci), 2018, 47(3): 250-254.
[10] HUANG Ting,ZHANG Xiaole,LIANG Liang,TAN Zheng,GAO Yue,LI Jianhua,SHU Qiang. Endoscopic lobectomy for 47 children with pulmonary sequestration[J]. J Zhejiang Univ (Med Sci), 2018, 47(3): 272-277.
[11] PENG Dandan,ZHOU Xudong. Parents' antibiotic use for children in Ningbo: knowledge, behaviors and influencing factors[J]. J Zhejiang Univ (Med Sci), 2018, 47(2): 156-162.
[12] ZHENG Qi,LU Meiping. Focus on pediatric rheumatic and immune diseases[J]. J Zhejiang Univ (Med Sci), 2018, 47(2): 213-217.
[13] WANG Liya, QIAN Yeqing, JIN Fan. Research progress on the safety of offsprings conceived by assisted reproductive technology[J]. J Zhejiang Univ (Med Sci), 2017, 46(3): 279-284.
[14] CHEN Yonghua,LIANG Li,FANG Yanlan,WANG Chunlin,LI Linfa,JIANG Tian'an. Iodine 131 joint radio frequency ablation treatment for child with hyperthyroidism goiter: one case report[J]. J Zhejiang Univ (Med Sci), 2017, 46(1): 89-91.
[15] CHEN Xiaohong, XU Yiping, LU Meiping. Clinical characteristics and etiology of children with hypereosinophilia[J]. J Zhejiang Univ (Med Sci), 2016, 45(3): 292-296.